1003-3734
2014 Issue 12
bian zhe tui jian
guo chao wei ;
guo chao wei ;
..............page:1343
..............page:1346
..............page:1347-1348
International Pharmacovigilance Flash
ben kan ;
ben kan ;
..............page:1349-1350
Tasimelteon,the first new drug for the treatment of non-24-hour sleep-wake disorder in totally blind individuals
DU Shan;SHU Yong-quan;Department of Pharmacy;Sichuan Provincial People’s Hospital;Sichuan Academy of Medical Science;
DU Shan;SHU Yong-quan;Department of Pharmacy;Sichuan Provincial People’s Hospital;Sichuan Academy of Medical Science;
..............page:1351-1353+1389
Effects on trends of global pharmaceutical R&D by “blockbuster drugs”
SU Yue;GUAN Zhen-he;GENG Xiang-nan;PU Run;AO Yi;China National Center for Biotechnology Development;Institute of Economics of the Chinese Academy of Social Sciences;
SU Yue;GUAN Zhen-he;GENG Xiang-nan;PU Run;AO Yi;China National Center for Biotechnology Development;Institute of Economics of the Chinese Academy of Social Sciences;
..............page:1354-1358+1397
Discussion on the author’s right of drug labeling
CHEN Bing;YANG Yun-xia;Chinese Pharmaceutical Association;China Pharmaceutical University;
CHEN Bing;YANG Yun-xia;Chinese Pharmaceutical Association;China Pharmaceutical University;
..............page:1359-1366
Evaluation and requirement for clinical trials of innovative vaccines
AI Xing;YANG Zhi-min;YANG Huan;Beijing Chaoyang District Center for Disease Control and Prevention;Center for Durg evaluation;CFDA;
AI Xing;YANG Zhi-min;YANG Huan;Beijing Chaoyang District Center for Disease Control and Prevention;Center for Durg evaluation;CFDA;
..............page:1367-1370+1417
Network pharmacological studies of Huoxiang Zhengqi pill in treating functional dyspepsia
SHI Qi-lin;MA Xiao-hui;YAN Lu-lu;XU Xiao-jie;SUN He;School of Pharmaceutical Science and Technology;Tianjin University;Department of Pharmacology and Toxicology;Tianjin Tasly Institute;Beijing National Laboratory for Molecular Sciences;State Key Laboratory Engineering;Peking University;
SHI Qi-lin;MA Xiao-hui;YAN Lu-lu;XU Xiao-jie;SUN He;School of Pharmaceutical Science and Technology;Tianjin University;Department of Pharmacology and Toxicology;Tianjin Tasly Institute;Beijing National Laboratory for Molecular Sciences;State Key Laboratory Engineering;Peking University;
..............page:1371-1377+1422
General requirements for incurred sample reanalysis in clinical pharmacokinetic studies and the interpretation
LI Min;SHI Ai-xin;LI Ke-xin;HU Xin;Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation;Department of Pharmacy;Beijing Hospital;
LI Min;SHI Ai-xin;LI Ke-xin;HU Xin;Beijing Key Laboratory of Drug Clinical Risk and Personalized Medication Evaluation;Department of Pharmacy;Beijing Hospital;
..............page:1378-1381
Impact on drug quality by change of API sourcing
WU Xiao-ming;ZHENG Qiang;Peking University;Center for Pharmaceutical Information and Engineering Research;Peking University;Department of Industry Engineering and Management of College of Engineering;Peking University;
WU Xiao-ming;ZHENG Qiang;Peking University;Center for Pharmaceutical Information and Engineering Research;Peking University;Department of Industry Engineering and Management of College of Engineering;Peking University;
..............page:1382-1389
Progress in research on structure-function of influenza virus polymerase as an antiviral target
LI Bei-bei;ZHOU Lin-ting;WU Jin-yan;Shanghai Institute of Biological Products Co.;Ltd.;
LI Bei-bei;ZHOU Lin-ting;WU Jin-yan;Shanghai Institute of Biological Products Co.;Ltd.;
..............page:1390-1397
Evaluation methods of colon specific drug delivery system in vitro and in vivo
WANG Shao-jing;ZHANG Xue-shun;Shandong University of Traditional Chinese Medicine;College of Pharmacy;The Hospital of Shandong University of Traditional Chinese Medicine;
WANG Shao-jing;ZHANG Xue-shun;Shandong University of Traditional Chinese Medicine;College of Pharmacy;The Hospital of Shandong University of Traditional Chinese Medicine;
..............page:1398-1401
Progress in research on small molecular inhibitors of Hedgehog signal pathway
MAO Yao-nan;HU Bing;CAI Jin;CHEN Jun-qing;ZONG Xi;WANG Peng;ZHANG Rui;JI Min;Pharmacy Section;Jiangsu Taizhou People’s Hospital;School of Chemistry and Chemical Engineering;Southeast University;School of Biological Science & Medical Engineering;Southeast University;
MAO Yao-nan;HU Bing;CAI Jin;CHEN Jun-qing;ZONG Xi;WANG Peng;ZHANG Rui;JI Min;Pharmacy Section;Jiangsu Taizhou People’s Hospital;School of Chemistry and Chemical Engineering;Southeast University;School of Biological Science & Medical Engineering;Southeast University;
..............page:1402-1409
Clinical guidelines of paliperidone palmitate
ZHANG Hong-yan;HUANG Ji-zhong;SI Tian-mei;SHU Liang;HAO Wei;MEI Qi-yi;ZHAO Jing-ping;YU Xin;ZHANG Ming-yuan;Peking University Sixth Hospital;Peking University Institute of Mental Health;Key Laboratory of Mental Health;Ministry of Health;Shanghai Mental Health Center;Institute of Mental Health;Xiangya No.2 Hospital of Central South University;Suzhou Guangji Hospital;
ZHANG Hong-yan;HUANG Ji-zhong;SI Tian-mei;SHU Liang;HAO Wei;MEI Qi-yi;ZHAO Jing-ping;YU Xin;ZHANG Ming-yuan;Peking University Sixth Hospital;Peking University Institute of Mental Health;Key Laboratory of Mental Health;Ministry of Health;Shanghai Mental Health Center;Institute of Mental Health;Xiangya No.2 Hospital of Central South University;Suzhou Guangji Hospital;
..............page:1410-1417
Impact of long-term treatment with risperidone or typical antipsychotics on QTc in schizophrenic patients
L Jian-bao;ZHANG Rong-zhen;LI Juan;YANG Fu-de;Beijing Huilongguan Hospital;
L Jian-bao;ZHANG Rong-zhen;LI Juan;YANG Fu-de;Beijing Huilongguan Hospital;
..............page:1418-1422
Relationship between N-acetyltransferase 2 genotype and concentration of Isoniazid aminosalicylate in the plasma of tuberculosis patients
XU Fei-hong;AN Hui-ru;ZHAO Guan-ren;ZHANG Jun-xian;LIANG Yan;YANG You-rong;WU Xue-qiong;Hebei North University;PLA Tuberculosis Research Institute;The 309th Hospital of PLA;Pharmacy department;The 309th Hospital of PLA;
XU Fei-hong;AN Hui-ru;ZHAO Guan-ren;ZHANG Jun-xian;LIANG Yan;YANG You-rong;WU Xue-qiong;Hebei North University;PLA Tuberculosis Research Institute;The 309th Hospital of PLA;Pharmacy department;The 309th Hospital of PLA;
..............page:1423-1426
Different doses of alprostadil combined with epalrestat treatment efficacy observation of diabetic painful nerve lesions
JIN Hai-jia;REN Fang;Armed Police Zhejiang Corps Hospital in Jiaxing;
JIN Hai-jia;REN Fang;Armed Police Zhejiang Corps Hospital in Jiaxing;
..............page:1427-1430+1437
Anti-tumor activity of SM1052,a novel artemisinin derivative,in the human endometrial carcinoma RL95-2 cells
ZHOU Jie-yun;XIE Shu-wu;ZHANG Yu;LI Guo-ting;GUI You-lun;LI Ying;ZHU Yan;Shanghai Institute of Planned Parenthood Research;NPFPC Laboratory of Contraception and Devices;Shanghai Engineer and Technology Research Center of Reproductive Health Drug and Devices;Shanghai Institute of Materia Medica;Chinese Academy of Sciences;Fudan University;
ZHOU Jie-yun;XIE Shu-wu;ZHANG Yu;LI Guo-ting;GUI You-lun;LI Ying;ZHU Yan;Shanghai Institute of Planned Parenthood Research;NPFPC Laboratory of Contraception and Devices;Shanghai Engineer and Technology Research Center of Reproductive Health Drug and Devices;Shanghai Institute of Materia Medica;Chinese Academy of Sciences;Fudan University;
..............page:1431-1437
Synthesis of benzene substituted hydroxyl acids as histone deacetylase inhibitors and evaluation of antitumor activity in vitro
HE Dian;MA Shang-xian;GUO Qing-xin;MOU Jian-ping;Institute of Pharmaceutical Chemistry;Lanzhou University;
HE Dian;MA Shang-xian;GUO Qing-xin;MOU Jian-ping;Institute of Pharmaceutical Chemistry;Lanzhou University;
..............page:1438-1442+1446
Synthesis of UNC1215,an antagonist for treating malignant brain tumor
LUO Gang;WANG Ying-ying;LIU Xiao;CHEN Yu-ying;Sichuan Industrial Institute of Antibiotics;Chengdu University;
LUO Gang;WANG Ying-ying;LIU Xiao;CHEN Yu-ying;Sichuan Industrial Institute of Antibiotics;Chengdu University;
..............page:1443-1446
Formula and preparation of shell vaginal ring containing mifepristone
DUAN Xue-yan;WANG Yan-kun;NING Mei-ying;WANG Jie-dong;LI Chun-xiao;Center of Drugs and Medical Polymer Materials;National Research Institute for Family Planning;School of Pharmaceutical Sciences;Shenyang Pharmaceutical University;Reproductive Physiology Laboratory;National Research Institute for Family Planning;Graduate School of Peking Union Medical College;
DUAN Xue-yan;WANG Yan-kun;NING Mei-ying;WANG Jie-dong;LI Chun-xiao;Center of Drugs and Medical Polymer Materials;National Research Institute for Family Planning;School of Pharmaceutical Sciences;Shenyang Pharmaceutical University;Reproductive Physiology Laboratory;National Research Institute for Family Planning;Graduate School of Peking Union Medical College;
..............page:1447-1453
LC-MS determination of plasma drug concentration after vaginal administration of susutained release intravaginal ring containing mifepristone in rabbits
DUAN Xue-yan;WANG Yan-kun;NING Mei-ying;ZHANG Ying;LIU Ying;LI Chun-xiao;Centre of Drugs and Medical Polymer Materials;National Research Institute for Family Planning;School of Pharmaceutical Sciences;Shenyang Pharmaceutical University;Graduate School of Peking Union Medical College;
DUAN Xue-yan;WANG Yan-kun;NING Mei-ying;ZHANG Ying;LIU Ying;LI Chun-xiao;Centre of Drugs and Medical Polymer Materials;National Research Institute for Family Planning;School of Pharmaceutical Sciences;Shenyang Pharmaceutical University;Graduate School of Peking Union Medical College;
..............page:1454-1457+1470
Impact of powder properties on vacuum filling performance
WANG Lei;CHEN Fang-xiao;ZENG Huan-xiang;FU Xiao-wei;Shenzhen Zhijun Pharmaceutical. Co.;Ltd.;Freeman Technology;
WANG Lei;CHEN Fang-xiao;ZENG Huan-xiang;FU Xiao-wei;Shenzhen Zhijun Pharmaceutical. Co.;Ltd.;Freeman Technology;
..............page:1458-1461
Treatment adjustment based on PK /PD theory in a patient of intracranial infection complicated by bone marrow suppression
HE Zhong-fang;WANG Xiao-hua;WU Xin-an;CHEN Xiao-wan;Department of Pharmacy;First Hospital of Lanzhou University;Department of Otolaryngology Head and Neck Surgery;First Hospital of Lanzhou University;
HE Zhong-fang;WANG Xiao-hua;WU Xin-an;CHEN Xiao-wan;Department of Pharmacy;First Hospital of Lanzhou University;Department of Otolaryngology Head and Neck Surgery;First Hospital of Lanzhou University;
..............page:1462-1464
Causal determination of the adverse events and adverse drug reactions in drug clinical trials
LI Bo;GAO Rui;LI Rui;LU Fang;ZI Ming-jie;LI Qing-na;TANG Xu-dong;Drug Clinical Trial Institution of Xiyuan Hospital;China Academy of Chinese Medical Sciences;
LI Bo;GAO Rui;LI Rui;LU Fang;ZI Ming-jie;LI Qing-na;TANG Xu-dong;Drug Clinical Trial Institution of Xiyuan Hospital;China Academy of Chinese Medical Sciences;
..............page:1465-1470